As the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, STELARA provides a new therapeutic option for children six years of age and older living with active psoriatic ...

On May 5, 2025, Teva and Alvotech announced that the U.S. Food and Drug Administration (FDA) approved SELARSDI (ustekinumab-aekn) injection as an interchangeable biosimilar to the reference product ...

Teva Pharmaceuticals and Alvotech announced that the Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with Stelara (ustekinumab). As of April 30, 2025 ...

Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

Savings and financial assistance programs are available for Stelara, such as Stelara withMe and J&J withME. Stelara might cost less with insurance than without it. Savings options are available for ...

Stelara is a biologic medicine used to treat moderate to severe Crohn’s disease and ulcerative colitis. Crohn’s disease and ulcerative colitis are inflammatory bowel diseases that cause inflammation ...

(RTTNews) - Bio-Thera Solutions Ltd and Hikma Pharmaceuticals PLC announced that the U.S. Food and Drug Administration has approved STARJEMZA (ustekinumab-hmny) Injection, a biosimilar referencing ...

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the ...